GlassScriptPhysician profile
Agha Khan
NPI 1881655660
$1,699.05
in general payments reported to CMS, 2019-2025
23 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2022: $150 · 2023: $680 · 2024: $291 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Travel and Lodging: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.78 |
| Travel and Lodging | $299.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $407.00 | 2023 | Versacross Access Solution, Watchman Access System |
| Abiomed | $176.89 | 2022-2023 | Impella |
| Shockwave Medical, INC | $147.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $107.84 | 2019-2025 | |
| Surmodics, INC. | $100.43 | 2025 | Pounce Thrombectomy, Pounce Venous Thrombectomy System, Pounce Thrombectomy System |
| Amgen INC. | $95.37 | 2023-2025 | Repatha, Repatha |
| Daiichi Sankyo INC. | $79.86 | 2023-2024 | Injectafer |
| Pfizer INC. | $76.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.10 | 2019-2025 | Farxiga |
| Scpharmaceuticals INC. | $53.97 | 2024 | |
| Irhythm Technologies, INC. | $49.47 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Innovation Technologies INC | $49.38 | 2022 | |
| Gilead Sciences, INC. | $48.24 | 2019 | |
| Alnylam Pharmaceuticals INC. | $37.63 | 2019-2023 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.30 | 2022-2024 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.94 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $24.95 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Edwards Lifesciences Corporation | $24.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.92 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.26 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $15.53 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $12.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.